Calithera Biosciences (CALA) Announces Quarterly Earnings Results

Calithera Biosciences (NASDAQ:CALA) issued its earnings results on Thursday. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.18), Fidelity Earnings reports.

Calithera Biosciences stock traded down $0.19 during trading hours on Friday, hitting $6.06. The stock had a trading volume of 95,578 shares, compared to its average volume of 116,206. The stock has a market capitalization of $237.31 million, a PE ratio of -4.07 and a beta of 2.21. Calithera Biosciences has a 12-month low of $3.55 and a 12-month high of $6.90.

A hedge fund recently raised its stake in Calithera Biosciences stock. Geode Capital Management LLC grew its position in Calithera Biosciences Inc (NASDAQ:CALA) by 26.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 348,667 shares of the biotechnology company’s stock after buying an additional 73,250 shares during the period. Geode Capital Management LLC owned approximately 0.91% of Calithera Biosciences worth $1,398,000 as of its most recent SEC filing. 55.43% of the stock is currently owned by institutional investors.

Separately, ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a report on Friday, March 15th.

COPYRIGHT VIOLATION WARNING: “Calithera Biosciences (CALA) Announces Quarterly Earnings Results” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Read More: What is the Fibonacci sequence?

Earnings History for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with's FREE daily email newsletter.